𝐌𝐚𝐫𝐤 𝐂𝐮𝐛𝐚𝐧 𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐞𝐬 𝐭𝐡𝐞 𝐒𝐭𝐞𝐥𝐚𝐫𝐚 𝐁𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫 𝐏𝐫𝐢𝐜𝐞 𝐖𝐚𝐫 Mark Cuban @mcuban is once again exposing the economic contradictions of the drug channel. The @costplusdrugs launch of Starjemza directly challenges PBM-affiliated

𝐂𝐢𝐠𝐧𝐚 ‘𝐑𝐞𝐛𝐚𝐭𝐞-𝐅𝐫𝐞𝐞’ 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐲 𝐌𝐨𝐝𝐞𝐥 𝐖𝐢𝐥𝐥 𝐓𝐞𝐬𝐭 𝐄𝐦𝐩𝐥𝐨𝐲𝐞𝐫 𝐑𝐞𝐥𝐢𝐚𝐧𝐜𝐞 𝐎𝐧 𝐑𝐞𝐯𝐞𝐧𝐮𝐞 𝐒𝐭𝐫𝐞𝐚𝐦 Great article from Cathy Kelly in The Pink Sheet on Cigna's new #PBM approach and what it might mean for employers who rely on

𝐓𝐡𝐞 𝐍𝐞𝐱𝐭 𝐏𝐡𝐚𝐬𝐞 𝐨𝐟 𝐕𝐞𝐫𝐭𝐢𝐜𝐚𝐥 𝐈𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐢𝐨𝐧: 𝐖𝐡𝐨𝐥𝐞𝐬𝐚𝐥𝐞𝐫𝐬 𝐉𝐨𝐢𝐧 𝐭𝐡𝐞 𝐆𝐚𝐦𝐞 Appreciate Jennifer P. Ungru of Jones Walker LLP highlighting DCI’s latest analysis on how the Big Three—Cencora, Cardinal Health, and McKesson—are expanding

💡𝐄𝐦𝐩𝐥𝐨𝐲𝐞𝐫𝐬 𝐚𝐫𝐞 𝐃𝐫𝐢𝐯𝐢𝐧𝐠 𝐏𝐁𝐌 𝐄𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧 According to @wtwcorporate’s 2025 Healthcare Survey, employers plan to move aggressively to reshape PBM relationships. By 2027: ✅ 75% will have taken their PBM out to bid ✅ 35% will conduct acquisition cost

𝐂𝐚𝐧 𝐒𝐭𝐚𝐭𝐞𝐬 𝐑𝐞𝐪𝐮𝐢𝐫𝐞 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐎𝐟 340𝐁-𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭𝐞𝐝 𝐃𝐫𝐮𝐠𝐬 𝐓𝐨 𝐔𝐧𝐥𝐢𝐦𝐢𝐭𝐞𝐝 𝐂𝐨𝐧𝐭𝐫𝐚𝐜𝐭 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐢𝐞𝐬? Excellent analysis from Steven Boranian of Reed Smith breaking down the key legal questions at the heart of state #340B

💊 𝐍𝐞𝐰 𝐄𝐯𝐢𝐝𝐞𝐧𝐜𝐞: 𝐂𝐨𝐩𝐚𝐲 𝐀𝐜𝐜𝐮𝐦𝐮𝐥𝐚𝐭𝐨𝐫 𝐁𝐚𝐧𝐬 𝐇𝐞𝐥𝐩 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬 For years, insurers’ copay #accumulator programs have blocked patients from using manufacturer assistance. A new study finds that state bans on accumulators work: ➡️ Patient

Counterintuitive #healthcare fact: Across 12 major countries, net #drug spending accounts for just 9% to 21% of total #healthcare costs. Despite the overheated political rhetoric, U.S. drug spending is (and has been) squarely in the middle of the pack. Everything in the U.S.

🚀 𝐃𝐂𝐋𝐅 2026 𝐒𝐞𝐬𝐬𝐢𝐨𝐧 𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭: 𝐖𝐡𝐚𝐭'𝐬 𝐍𝐞𝐱𝐭 𝐟𝐨𝐫 𝐏𝐫𝐨𝐯𝐢𝐝𝐞𝐫-𝐀𝐝𝐦𝐢𝐧𝐢𝐬𝐭𝐞𝐫𝐞𝐝 𝐃𝐫𝐮𝐠𝐬 𝐚𝐧𝐝 𝐁𝐮𝐲-𝐚𝐧𝐝-𝐁𝐢𝐥𝐥 How are leading payers, providers, and distributors shaping the future of provider-administered drugs? Join this

𝐐𝐮𝐞𝐬𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐡𝐞 𝐝𝐚𝐲: Why do we call it a randomized, double-blind, placebo-controlled study… when “Trick or Treatment” would’ve worked just fine?🎃💊 Happy Halloween, everyone! 👻🧛‍♂️🍬🦇🕷️🐈‍⬛

The last Rite Aid in Center City has been reincarnated as something spookier. Happy Halloween Eve, everyone! 🎃

From @OutcomesOne: 𝐀𝐬 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐚𝐜𝐞𝐬 𝐅𝐢𝐧𝐚𝐧𝐜𝐢𝐚𝐥 𝐏𝐫𝐞𝐬𝐬𝐮𝐫𝐞, 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐲 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐬 𝐌𝐞𝐚𝐬𝐮𝐫𝐚𝐛𝐥𝐞 𝐈𝐦𝐩𝐚𝐜𝐭 Learn about Outcomes’ pharmacist-led interventions solution: https://t.co/SG3Gka13Iw Read the article:

Good article on @Cigna's "rebate-free" announcement by Lauren Clason @blaw 👉

𝐂𝐢𝐠𝐧𝐚’𝐬 𝐑𝐞𝐛𝐚𝐭𝐞-𝐅𝐫𝐞𝐞 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐲 𝐌𝐨𝐝𝐞𝐥: 𝐓𝐡𝐫𝐞𝐞 𝐑𝐞𝐚𝐥𝐢𝐭𝐢𝐞𝐬 𝐁𝐞𝐡𝐢𝐧𝐝 𝐈𝐭𝐬 𝐋𝐚𝐭𝐞𝐬𝐭 𝐏𝐮𝐬𝐡 𝐭𝐨 𝐏𝐨𝐩 𝐭𝐡𝐞 𝐆𝐫𝐨𝐬𝐬-𝐭𝐨-𝐍𝐞𝐭 𝐁𝐮𝐛𝐛𝐥𝐞 Real reform or just a rerun? Read my analysis on 𝘋𝘳𝘶𝘨 𝘊𝘩𝘢𝘯𝘯𝘦𝘭𝘴 👇

𝐃𝐫𝐮𝐠 𝐂𝐡𝐚𝐧𝐧𝐞𝐥𝐬 𝐍𝐞𝐰𝐬 𝐑𝐨𝐮𝐧𝐝𝐮𝐩, 𝐎𝐜𝐭𝐨𝐛𝐞𝐫 2025 🎃 It’s time for the 𝘋𝘳𝘶𝘨 𝘊𝘩𝘢𝘯𝘯𝘦𝘭𝘴 Halloween roundup of terrifying tales from the dark corners of the healthcare system. This month’s tricks and treats include: 🧛 𝐕𝐚𝐦𝐩𝐢𝐫𝐢𝐜! How

🚨𝐌𝐨𝐫𝐞 𝐞𝐯𝐢𝐝𝐞𝐧𝐜𝐞 𝐭𝐡𝐚𝐭 𝐭𝐡𝐞 𝐠𝐫𝐨𝐬𝐬-𝐭𝐨-𝐧𝐞𝐭 𝐛𝐮𝐛𝐛𝐥𝐞 𝐢𝐬 𝐬𝐭𝐚𝐫𝐭𝐢𝐧𝐠 𝐭𝐨 𝐩𝐨𝐩🚨 According to Bloomberg, Cigna Healthcare will remove rebates from its fully insured health plan members (~2 M lives). By passing rebate value directly to patients

🚨 𝐋𝐚𝐬𝐭 𝐃𝐚𝐲 𝐟𝐨𝐫 𝐒𝐩𝐞𝐜𝐢𝐚𝐥 𝐋𝐚𝐮𝐧𝐜𝐡 𝐏𝐫𝐢𝐜𝐢𝐧𝐠! 🚨 Today (October 27) is your final chance to save on DCI’s new 2025–26 𝑬𝒄𝒐𝒏𝒐𝒎𝒊𝒄 𝑹𝒆𝒑𝒐𝒓𝒕 𝒐𝒏 𝑷𝒉𝒂𝒓𝒎𝒂𝒄𝒆𝒖𝒕𝒊𝒄𝒂𝒍 𝑾𝒉𝒐𝒍𝒆𝒔𝒂𝒍𝒆𝒓𝒔 𝒂𝒏𝒅 𝑺𝒑𝒆𝒄𝒊𝒂𝒍𝒕𝒚

𝐓𝐡𝐞 𝐡𝐢𝐝𝐝𝐞𝐧 𝐜𝐨𝐬𝐭 𝐨𝐟 𝐜𝐨𝐢𝐧𝐬𝐮𝐫𝐚𝐧𝐜𝐞 💸 Even in 2025, many employees still pay list prices for prescriptions. High-deductible health plans keep shifting costs to workers: ➡️ 1 in 3 covered employees are in an HDHP ➡️ About half pay coinsurance instead of a

🚀 𝐃𝐂𝐋𝐅 2026 𝐒𝐞𝐬𝐬𝐢𝐨𝐧 𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭: 𝐓𝐡𝐞 𝐕𝐢𝐞𝐰 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐞𝐫 How are pharmaceutical manufacturers preparing for the evolution of the drug channel? At the 2026 𝐃𝐫𝐮𝐠 𝐂𝐡𝐚𝐧𝐧𝐞𝐥𝐬 𝐋𝐞𝐚𝐝𝐞𝐫𝐬𝐡𝐢𝐩 𝐅𝐨𝐫𝐮𝐦, three

From @EVERSANAcompany: 𝐋𝐞𝐭’𝐬 𝐁𝐞 𝐃𝐈𝐑𝐄𝐂𝐓: 𝐖𝐞 𝐇𝐚𝐯𝐞 𝐚𝐧 𝐀𝐜𝐜𝐞𝐬𝐬 𝐚𝐧𝐝 𝐀𝐟𝐟𝐨𝐫𝐝𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐏𝐫𝐨𝐛𝐥𝐞𝐦 𝐭𝐨 𝐒𝐨𝐥𝐯𝐞 Learn more: https://t.co/doSv0qdStt Read the article: https://t.co/BQbnkkUQ4x #sponsored

𝐔𝐧𝐬𝐮𝐬𝐭𝐚𝐢𝐧𝐚𝐛𝐥𝐞 (𝐚𝐝𝐣𝐞𝐜𝐭𝐢𝐯𝐞): 𝘯𝘰𝘵 𝘤𝘢𝘱𝘢𝘣𝘭𝘦 𝘰𝘧 𝘣𝘦𝘪𝘯𝘨 𝘱𝘳𝘰𝘭𝘰𝘯𝘨𝘦𝘥 𝘰𝘳 𝘤𝘰𝘯𝘵𝘪𝘯𝘶𝘦𝘥 People keep using that word to describe U.S. healthcare premiums. Judging by the past 25 years (👇), I do not think it means what they think it